Galderma's Sculptra turned 25 in 2024, marking a quarter-century since its introduction as the first poly-L-lactic acid (PLLA) aesthetic injectable. In that time it has gained a new name — biostimulator — a new set of body indications, and a new generation of patients. As the aesthetics industry moves toward treatments that work with the body's own biology, Sculptra's moment has arguably arrived.
The Science of PLLA-SCA
Sculptra's active ingredient is poly-L-lactic acid (PLLA), suspended in a carboxymethylcellulose (CMC) carrier with sodium chloride. When injected into the deep dermis or subdermis, PLLA microparticles are gradually absorbed by the body and trigger a controlled wound-healing response. This stimulates fibroblasts to produce new collagen — specifically Type I collagen, the structural collagen responsible for skin firmness and elasticity. The CMC carrier provides immediate water-based volume that resorbs over days; the PLLA-driven collagen then builds gradually over weeks to months.
Galderma's current formulation is designated PLLA-SCA (suspension of calibrated microspheres), with consistent particle size that supports predictable collagen induction. Unlike hyaluronic acid fillers, Sculptra does not add or displace tissue — it rebuilds it. This distinction is central to its growing appeal: the result looks and feels like natural tissue because, in a meaningful sense, it is.
Growing Beyond the Face
A landmark development in 2023 was Sculptra receiving MDR (Medical Device Regulation) certification for body indications in the EU — expanding its clinical use to the gluteal area, posterior thighs, décolletage, and upper arms. These four new anatomical areas address treatment goals ranging from cellulite appearance improvement, to skin firmness enhancement, to lift and contouring. This makes Sculptra one of the very few injectable products with robust regulatory support for both facial and body use.
The FDA had already approved Sculptra for correction of fine lines and wrinkles in the cheek area in 2023, adding to its long-established approval for facial lipoatrophy. At AMWC (the Aesthetic and Anti-Aging Medicine World Congress) in 2024, Galderma presented six new data posters on Sculptra — one of the largest single-product clinical presentations at the conference — reflecting the depth of the evidence base that has developed around it over 25 years.
How It Compares to HA Fillers
HA fillers and PLLA biostimulators serve different clinical goals, and comparing them directly misses the point. HA fillers produce immediate, reversible, precisely placeable volume. PLLA produces delayed, gradual, non-reversible tissue regeneration. For patients who want to see results immediately, HA fillers are appropriate. For patients who want results that develop over two to three months, look completely natural, and last two or more years, Sculptra offers an alternative that HA cannot match on longevity.
The combination approach — using HA filler for immediate structural correction and Sculptra for long-term collagen regeneration — has become a sophisticated treatment strategy in experienced hands. This mirrors a broader industry shift toward tissue quality as a treatment goal, rather than simple volume replacement.
Patient Selection and Realistic Expectations
Sculptra is not a quick fix. Results typically require two to three sessions spaced four to six weeks apart, and the collagen response takes three to six months to fully develop. Patients need to be well-informed about this timeline — and those who are tend to be among the most satisfied. Understanding what you are choosing, and why, is the foundation of every good treatment outcome.